This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Guadecitabine
- DrugBank Accession Number
- DB11918
- Background
Guadecitabine is under investigation for the treatment of Previously Treated Metastatic Colorectal Cancer.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Guadecitabine (DB11918)
- Weight
- Average: 557.417
Monoisotopic: 557.138375007 - Chemical Formula
- C18H24N9O10P
- Synonyms
- Guadecitabine
- External IDs
- SGI-110
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareArticaine The risk or severity of methemoglobinemia can be increased when Guadecitabine is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Guadecitabine is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Guadecitabine is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Guadecitabine is combined with Bupivacaine. Butacaine The risk or severity of methemoglobinemia can be increased when Guadecitabine is combined with Butacaine. Butamben The risk or severity of methemoglobinemia can be increased when Guadecitabine is combined with Butamben. Capsaicin The risk or severity of methemoglobinemia can be increased when Guadecitabine is combined with Capsaicin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Guadecitabine is combined with Chloroprocaine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Guadecitabine is combined with Cinchocaine. Cocaine The risk or severity of methemoglobinemia can be increased when Guadecitabine is combined with Cocaine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Guadecitabine Sodium 0RB89YH367 929904-85-8 XLHBNJPXFOZFNJ-BYKQGDNKSA-M
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as purine 2'-deoxyribonucleoside monophosphates. These are purine nucleotides with monophosphate group linked to the ribose moiety lacking a hydroxyl group at position 2.
- Kingdom
- Organic compounds
- Super Class
- Nucleosides, nucleotides, and analogues
- Class
- Purine nucleotides
- Sub Class
- Purine deoxyribonucleotides
- Direct Parent
- Purine 2'-deoxyribonucleoside monophosphates
- Alternative Parents
- 6-oxopurines / Hypoxanthines / Triazinones / Pyrimidones / Aminopyrimidines and derivatives / Aminotriazines / Dialkyl phosphates / 1,3,5-triazines / N-substituted imidazoles / Vinylogous amides show 9 more
- Substituents
- 1,3,5-triazine / 6-oxopurine / Alcohol / Alkyl phosphate / Amine / Amino-1,3,5-triazine / Aminopyrimidine / Aminotriazine / Aromatic heteropolycyclic compound / Azacycle show 28 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 2KT4YN1DP7
- CAS number
- 929901-49-5
- InChI Key
- GUWXKKAWLCENJA-WGWHJZDNSA-N
- InChI
- InChI=1S/C18H24N9O10P/c19-16-22-6-27(18(31)25-16)12-2-8(9(3-28)35-12)37-38(32,33)34-4-10-7(29)1-11(36-10)26-5-21-13-14(26)23-17(20)24-15(13)30/h5-12,28-29H,1-4H2,(H,32,33)(H2,19,25,31)(H3,20,23,24,30)/t7-,8-,9+,10+,11+,12+/m0/s1
- IUPAC Name
- {[(2R,3S,5R)-5-(4-amino-2-oxo-1,2-dihydro-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy}({[(2R,3S,5R)-5-(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy})phosphinic acid
- SMILES
- NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](COP(O)(=O)O[C@H]2C[C@@H](O[C@@H]2CO)N2C=NC(N)=NC2=O)O1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 71587872
- PubChem Substance
- 347828249
- ChemSpider
- 32701891
- ChEMBL
- CHEMBL3544916
- ZINC
- ZINC000043203165
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Acute Myeloid Leukemia 2 3 Completed Treatment Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome 1 2 Active Not Recruiting Treatment Acute Myeloid Leukemia / Chronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Recurrent Acute Myeloid Leukemia / Recurrent Myelodysplastic Syndrome 1 2 Active Not Recruiting Treatment Extensive-stage Small Cell Lung Cancer (SCLC) / Small Cell Lung Cancer (SCLC) 1 2 Active Not Recruiting Treatment High-risk Myelodysplastic Syndrome (MDS) 1 2 Active Not Recruiting Treatment Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma 1 2 Active Not Recruiting Treatment Urothelial Carcinoma 1 2 Completed Treatment Hepatocellular Carcinoma 1 2 Completed Treatment Myelodysplastic Syndrome 1 2 Completed Treatment Myeloproliferative Neoplasms (MPNs) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.89 mg/mL ALOGPS logP -2 ALOGPS logP -3.6 Chemaxon logS -2.3 ALOGPS pKa (Strongest Acidic) 1.79 Chemaxon pKa (Strongest Basic) 2.67 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 15 Chemaxon Hydrogen Donor Count 6 Chemaxon Polar Surface Area 271.03 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 120.45 m3·mol-1 Chemaxon Polarizability 49.74 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 21:00 / Updated at February 21, 2021 18:53